Tags

Type your tag names separated by a space and hit enter

Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer.
Mol Clin Oncol 2019; 11(5):517-522MC

Abstract

Survival outcome of ovarian suppression plus tamoxifen has been shown to be comparable with chemotherapy in premenopausal women; however, there are a few previous studies that compared this treatment to the current standard adriamycin and cyclophosphamide (AC) regimen. The aim of the present study was to compare the survival outcome of gonadotropin-releasing hormone (GnRH) agonist plus tamoxifen (GnRH-TAM) and chemotherapy AC plus tamoxifen (AC-TAM) in premenopausal patients with early breast cancer who were hormone receptor-positive. Premenopausal patients with early breast cancer who were treated at The Siriraj Hospital between January 2005 and December 2015 were retrospectively recruited. The inclusion criteria included newly diagnosed breast cancer, size ≤3 cm, node-negative and hormone receptor-positive. All patients received adjuvant systemic therapy and were divided into two groups. In the GnRH-TAM group, the patients received subcutaneous injection of 10.8 mg of goserelin every 3 months for 2-3 years and TAM (20 mg/day) for 5 years. In the AC-TAM group, AC was administered every 3 weeks for 4 cycles followed by TAM (20 mg/day) for 5 years. In total, 40 patients received GnRH-TAM and 130 patients received AC-TAM. The mean age at diagnosis was 44.4±6.3 years while the median follow up time was 77 (36-167) months. There was no mortality in either group and no significant difference in disease-free survival between the two groups. No adverse effect occurred and good compliance was observed in all patients who received GnRH-TAM. Treatment with GnRH-TAM resulted in a comparable survival outcome and better quality of life compared with AC-TAM.

Authors+Show Affiliations

Division of Head Neck and Breast Surgery, Department of Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.Division of Head Neck and Breast Surgery, Department of Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand. Department of Surgery, Rajavithi Hospital, Bangkok 10400, Thailand.Division of Head Neck and Breast Surgery, Department of Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.Division of Head Neck and Breast Surgery, Department of Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31620283

Citation

Sa-Nguanraksa, Doonyapat, et al. "Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients With Early Breast Cancer." Molecular and Clinical Oncology, vol. 11, no. 5, 2019, pp. 517-522.
Sa-Nguanraksa D, Krisorakun T, Pongthong W, et al. Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer. Mol Clin Oncol. 2019;11(5):517-522.
Sa-Nguanraksa, D., Krisorakun, T., Pongthong, W., & O-Charoenrat, P. (2019). Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer. Molecular and Clinical Oncology, 11(5), pp. 517-522. doi:10.3892/mco.2019.1913.
Sa-Nguanraksa D, et al. Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients With Early Breast Cancer. Mol Clin Oncol. 2019;11(5):517-522. PubMed PMID: 31620283.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer. AU - Sa-Nguanraksa,Doonyapat, AU - Krisorakun,Thitikon, AU - Pongthong,Wanee, AU - O-Charoenrat,Pornchai, Y1 - 2019/08/20/ PY - 2019/02/04/received PY - 2019/06/10/accepted PY - 2019/10/18/entrez PY - 2019/10/18/pubmed PY - 2019/10/18/medline KW - early breast cancer KW - endocrine therapy KW - gonadotropin-releasing hormone agonist KW - ovarian suppression KW - premenopause SP - 517 EP - 522 JF - Molecular and clinical oncology JO - Mol Clin Oncol VL - 11 IS - 5 N2 - Survival outcome of ovarian suppression plus tamoxifen has been shown to be comparable with chemotherapy in premenopausal women; however, there are a few previous studies that compared this treatment to the current standard adriamycin and cyclophosphamide (AC) regimen. The aim of the present study was to compare the survival outcome of gonadotropin-releasing hormone (GnRH) agonist plus tamoxifen (GnRH-TAM) and chemotherapy AC plus tamoxifen (AC-TAM) in premenopausal patients with early breast cancer who were hormone receptor-positive. Premenopausal patients with early breast cancer who were treated at The Siriraj Hospital between January 2005 and December 2015 were retrospectively recruited. The inclusion criteria included newly diagnosed breast cancer, size ≤3 cm, node-negative and hormone receptor-positive. All patients received adjuvant systemic therapy and were divided into two groups. In the GnRH-TAM group, the patients received subcutaneous injection of 10.8 mg of goserelin every 3 months for 2-3 years and TAM (20 mg/day) for 5 years. In the AC-TAM group, AC was administered every 3 weeks for 4 cycles followed by TAM (20 mg/day) for 5 years. In total, 40 patients received GnRH-TAM and 130 patients received AC-TAM. The mean age at diagnosis was 44.4±6.3 years while the median follow up time was 77 (36-167) months. There was no mortality in either group and no significant difference in disease-free survival between the two groups. No adverse effect occurred and good compliance was observed in all patients who received GnRH-TAM. Treatment with GnRH-TAM resulted in a comparable survival outcome and better quality of life compared with AC-TAM. SN - 2049-9450 UR - https://www.unboundmedicine.com/medline/citation/31620283/Survival_outcome_of_combined_GnRH_agonist_and_tamoxifen_is_comparable_to_that_of_sequential_adriamycin_and_cyclophosphamide_chemotherapy_plus_tamoxifen_in_premenopausal_patients_with_early_breast_cancer L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31620283/ DB - PRIME DP - Unbound Medicine ER -